Clinical Trials in the UK / NCT07288333
Recruiting
Phase 2
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
NCT07288333 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Schizophrenia
Investigational drug(s) / intervention(s)
NBI-1117570Placebo
NBI-1117570: Oral administration
Placebo: Oral administration
Study summary
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Eligibility
Key Inclusion Criteria:
* 18 to 55 years of age
* Primary diagnosis of schizophrenia ≥1 year before screening.
* Participant is experiencing an acute exacerbation or relapse of symptoms with onset less than 2 months before screening and currently requires hospitalization.
* Participant must have had a positive response to at least 1 antipsychotic therapy (other than clozapine) for the treatment of a prior acute relapse.
Key Exclusion Criteria:
* Considered to be at imminent risk of suicide or injury to self or others.
* History of epilepsy, seizures, or convulsions.
* Has orthostatic hypotension, or history of pulmonary hypertension, obstructive coronary artery disease, hypertrophic cardiomyopathy, myocardial infarction, coronary artery revascularization, heart failure, left ventricular hypertrophy, moderate or severe cardiac valvopathy, or other cardiovascular conditions or measures that would preclude participation.
* Currently taking prohibited medications.
* Pregnant or lactating.
Note: Additional inclusion/exclusion criteria may apply, per protocol.
Primary outcome measure(s)
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 35 — Day 35
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| Neurocrine Clinical Site | Kazanlak | Bulgaria | Recruiting |
| Neurocrine Clinical Site | Pazardzhik | Bulgaria | Recruiting |
| Neurocrine Clinical Site | Targovishte | Bulgaria | Recruiting |
| Neurocrine Clinical Site | Târgu Mureş | Romania | Recruiting |
| Neurocrine Clinical Site | London | United Kingdom | Recruiting |
| Neurocrine Clinical Site | Oxford | United Kingdom | Recruiting |
More Neurocrine Biosciences trials in the UK
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07288333 on ClinicalTrials.gov ↗ ← All trials in the UK